Central blood pressure in chronic kidney disease: Latest evidence and clinical relevance

Current Hypertension Reviews

Volumn 10, Issue 2, 2014, Pages 99-106

  Yuan, Mengshi ^a   Moody, William E ^a,b   Townend, Jonathan N ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Arterial stiffness; Central blood pressure; Chronic kidney disease

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERY CALCIFICATION; ARTICLE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; DRUG EFFECT; HEART CATHETERIZATION; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TONOMETRY; VASCULITIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RISK FACTOR;

BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; GLOMERULAR FILTRATION RATE; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84921745237     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/1573402111666141231145931     Document Type: Article

References (77)

1. Lesley AS, Suying L, Changchun W, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010; 55: S23-33.
2. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation. N Eng J Med 2004; 351: 1296-305.
4. Di Angelantonio E, Chowdhury R, Sarwar N, et al. Chronic kidney disease and risk of major cardiovascular and non-vascular mortality: prospective population based cohort study. BMJ 2010; 341: c4986.
5. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28: 478-83.
6. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal followup and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-63.
7. Parfrey PS, Foley RN. The clinical epidemiology of cardiovascular disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-15.
8. Boon N, Boyle R, Bradbury K, et al. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100: ii1-67.
9. Moody WE, Edwards NC, Chue CD, et al. Arterial disease in chronic kidney disease. Heart 2013; 6: 365-72.
10. Guerin AP, Pannier B, Marchais SJ, et al. Artertial structure and function in end-stage renal disease. Curr Hypertens Rep 2008; 10: 107-11.
11. Jungers P, Massy ZA, Nguyen Khoa T, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dia Transplant 1997; 12: 2597-602.
12. Baigent C, Landry M. Study of heart and renal protection (SHARP). Kidney Int Suppl 2003; 63: 207-10.
13. US Renal Data System (USRDS). Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
14. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly related to vascular disease and outcome than does brachial pressure: the strong heart study. Hypertension 2007; 50: 197-203.
15. Pini R, Cavallini MC, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular veents in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol 2008; 51: 848-55.
16. Protogerou AD, Papaioannou TG, Blacher J, et al. Central blood pressure: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target? J Hypertens 2007; 25: 265-72.
17. Kroeker EJ, Wood EH. Comparison of simultaneously recorded central and peripheral arterial pressure pulses during rest, exercise and tilted position in man. Circ Res 1955; 3: 623-32.
18. Pauca AL, O’Rourke MF, Kon MD. Prospective evaluation of method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38: 932-7.
19. Albaladejo P, Copie X, Boutouyrie P, et al. Heart rate, arterial stiffness, and wave reflections in paced patients. Hypertension 2001; 38: 949-52.
20. Wilkinson IB, Mohammad NH, Tyrrell S, et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens 2002; 15: 24-30.
21. Mahmud A, Feely J. Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension 2003; 41: 183-7.
22. Wilkinson IB, Prasad K, Hall IR, et al. Increased central pulse pressure and augmentation index in subjects with hypercholesterolaemia. J Am Coll Cardiol 2002; 39: L1005-11.
23. Protogerou AD, Blacher J, Mavrikakis M, et al. Increased pulse pressure amplification in treated hypertensive subjects with metabolic syndrome. Am J Hypertens 2007; 20: 127-33.
24. McEniery CM, Yasmin, McDonnell B, et al. Central pressures: variability and impact of cardiovascular risks factors: the Anglo- Cardiff Collaborative Trial II. Hypertension 2008; 51: 1476-82.
25. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events; the Framingham Heart Study. Circulation 2010; 121: 505-11.
26. Segers P, Mahieu D, Kips J, et al. Amplification of pulse pressure in the upper limb in healthy, middle-aged men and women. Hypertension 2009; 42: 414-20.
27. O’Rouke MF, Adji A, Central pressure and pulse wave amplification in the upper arm. Hypertension 2010; 55: e1-2.
28. Chen CH, Ting CT, Nussbacher A, et al. Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure. Hypertension 1996; 27: 168-75.
29. Kelly R, Karamanoglu M, Gibbs H, et al. Non-invasive carotid pressure wave registration as an indicator of ascending aortic pressure. J Vasc Med Biol 1989; 1: 241-7.
30. O’Rourke MF, Adji A. Noninvasive studies of central aortic pressure. Curr Hypertens Rep 2012; 14: 8-20.
31. Kelly R, Hayward C, Ganis J, et al. Non-invasive registration of the arterial pressure pulse waveform using high fidelity applanation tonometry. J Vasc Med Biol 1989; 1: 142-9.
32. O’Rourke MF, Lei J, Gallagher DE, et al. Determination of the ascending aortic pressure wave augmentation from the radial artery pressure pulse contours in humans. Circulation 1995; 92: 745.
33. William B, Lacy PS, Yan P, et al. Development and validation of a novel method to derive central aortic systolic pressure from the radial pressure waveform using an N-point moving average method. J Am Coll Cardiol 2011; 57: 951-61.
34. Shih YT, Cheng HM, Sung SH, et al. Quantification of the calibration error in the transfer function-derived central aortic blood pressure. Am J Hypertens 2011; 24: 1312-7.
35. Mahieu D, Kips J, Rietzchel ER, et al. Noninvasive assessment of central and peripheral arterial pressure (waveforms); implications of calibration methods. J Hypertens 2010; 28: 300-5.
36. Roman MJ, Deveruex RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure. The Strong Heart Study. Hypertension 2007; 50: 197-203.
37. Laurent S, Cockcroft J, Van Borterl L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-605.
38. Kullo IJ, Malik AR. Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification. J Am Coll Cardiol 2007; 49: 1413-26.
39. Roman MJ, Devereux RB, Kiser JR, et al. High central pulse pressure is independently associated with adverse cardiovascular outcome. The Strong Heart Study. J Am Coll Cardiol 2009; 54: 1730-4.
40. Pini R, Cavallini MC, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol 2008; 51: 2432-9.
41. Benetos A, Thomas F, Joly L, et al. Pulse pressure amplification a mechanical biomarker of cardiovascular risk. J Am Coll Cardiol 2010; 55: 1032-7.
42. Ng KP, Moody WE, Chue CD, et al. Central pulse pressure in patients with chronic kidney disease and in renal transplant recipients. J Hum Hypertens 2014; 28: 180-5.
43. Vlachopoulos C, Aznaouridis K, O’Rourke, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systemic review and meta-analysis. Eur Heart J 2010; 31: 1865-71.
44. Townsend RR, Feldman HI. CKD: past problems, current challenges and future facets. J Am Soc Nephrol 2009; 8: 1-5.
45. Astor BC, Hallan SI, Miller ER III, et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008; 167: 1226-34.
46. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46: 200-4.
47. Hsu CY, McCulloch CE, Darbinian J, et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 8: 923-8.
48. Blacher J, Guerin AP, Panniert B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-9.
49. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-8.
50. Benetos A, Gautier S, Labat C, et al. Mortality and cardiovascular events are best predicted by low central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly nursing home subjects: the PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population) study. J Am Coll Cardiol 2012; 16: 1503-11.
51. Pannier B, Guerin AP, Marchais SJ, et al. Stiffness of capacitive and conduit arteries. Prognostic significance for end-stage renal disease patients. Hypertension 2005; 45: 592-6.
52. Takenaka T, Mimura T, Kanno Y, et al. Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases. Am J Nephrol 2005; 25: 417-24.
53. Taal MW, Sigrist MK, Fakis A, et al. Markers of arterial stiffness are risk factos for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5. Nephron Clin Pract 2007; 107: 177-81.
54. Wang MC, Tsai WC, Chen YJ, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005; 45: 494-501.
55. Mourad JJ, Pannier B, Blacher J, et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 2001; 59: 1834-41.
56. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack troal (ALLHAT). JAMA 2002; 288: 2981-97.
57. Stassen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-15.
58. Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 2007; 50: 219-27.
59. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angio Aldos Syst 2000; 1: 18-20.
60. Dalof B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
61. Carlberg B, Samuelsson O. Atenolol in hypertension; is it a wise choice? Lancet 2004; 364: 1684-9.
62. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53.
63. Deary AJ, Schumann AL, Murfet H, et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clinical Science 2002; 103: 493-9.
64. Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug classes on central aortic pressure. Am H Hypertens 2004; 17: 118-23.
65. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54: 409-13.
66. London GM, Asmar RG, O’Rourke MF, et al. Mechanism of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects; comparison with atenolol. J Am Coll Cardiol 2004; 43: 92-9.
67. Boutouyrie P, Achouba A, Trunet P, et al. Amlodipine-valsartan combination decreases central blood pressure more effectively than the amlodipine-atenolol combination. The EXPLOR study. Hypertension 2010; 55: 1314-22.
68. William B, Lacy PS, Cruickshank K, et al. CAFE investigators; Anglo-Scandinavian Cardiac Outcomes Trial Invetigators; CAFE steering committee and writing committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinicl outcomes. Circulation 2006; 113: 1213-25.
69. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51: 161-7.
70. Struthers AD. Aldosterone blockade in cardiovascular disease. Heart 2004; 90: 1229-34.
71. Schrier RW, Masoumi A, Elhassan E. Aldosterone: role in edematous disorders, hypertension chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010; 6: 1132-40.
72. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in earlystage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009; 6; 505-12.
73. Edwards NC, Steeds RP, Chue CD, et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012; 3: 447-54.
74. Chue CD, Edwards NC, Moody WE, Steeds RP, Townend JN, Ferro CJ. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 2012; 98: 219-24.
75. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-408.
76. Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013; 24: 842-52.
77. Weber T, Wassertheurer S, Rammer M, et al. Validation of a brachial cuff-based method for estimating central systolic blood pressure. Hypertension 2011; 58: 825-32.